Monomeric IgG2 enhances Ig production and proliferation in human B cells.
The effect of purified polyclonal human IgG subclasses on B-cell responses was studied using the human IgA-producing B-cell line GM-1056. IgG2 at concentrations of 0.01-1 microgram/mL enhanced both IgA production and proliferation, while IgG1, IgG3, and IgG4 each failed to do so at tested concentrations between 0.001 and 10 micrograms/mL. This enhancement was Fc gamma R mediated, since IgG2 Fc fragments enhanced IgA production and proliferation to the same extent as did the whole IgG2 molecule, whereas F(ab')2 fragments did not. However, in contrast to monomeric IgG2, aggregated IgG2, which was expected to bind Fc gamma RII on B cells, affected neither IgA production nor proliferation. Similarly, anti-CDw32 mAb (2E1, anti-Fc gamma RII), anti-CD 64 mAb (32.2 anti-Fc gamma RI), and anti-CD16 mAb (Leu 11a, anti-Fc gamma RIII) mAb each failed to stimulate GM-1056 cells, and more importantly did not block IgG2-induced stimulation. Of various cytokines tested, including IFN-alpha, IFN-gamma, IL-1 beta, IL-2, IL-3, IL-4, IL-5, and IL-6, IL-6 alone augmented IgG2-induced enhancement of IgA production and proliferation. Moreover, the IL-6 effect was lost following preabsorption with anti-IL-6 antibody but not following preabsorption with control antibody. IgG2 also enhanced Ig production and proliferation in tonsillar large activated B cells, while IgG1, IgG3 and IgG4 each failed to do so. In contrast, IgG2 had no effect on Ig production and proliferation in tonsillar small resting B cells or SAC-stimulated small B cells. IgG2-induced enhancement of Ig production and proliferation in large B cells was not blocked by 2E1, 32.2, or Leu 11a, while enhancement was augmented in a specific fashion by IL-6. These results indicate that monomeric IgG2 specifically enhances B cell responses via an Fc gamma R receptor distinct from Fc gamma RI, Fc gamma RII, and Fc gamma RIII, and that IL-6 may play a role in augmenting this response.
Kimata
H
H
Department of Pediatrics, Faculty of Medicine, Kyoto University Hospital, Japan.
Yoshida
A
A
Ishioka
C
C
Jiang
Y
Y
Kusunoki
T
T
Mikawa
H
H
D001402:B-Lymphocytes / Q000276:immunology*; D002455:Cell Division; D002460:Cell Line; D016207:Cytokines / Q000494:pharmacology*; D006801:Humans; D007070:Immunoglobulin A / Q000096:biosynthesis; D007128:Immunoglobulin Fragments / Q000494:pharmacology; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000494:pharmacology*; D007075:Immunoglobulin M / Q000096:biosynthesis; D007136:Immunoglobulins / Q000096:biosynthesis*; D015850:Interleukin-6 / Q000494:pharmacology; D008213:Lymphocyte Activation; D014066:Palatine Tonsil / Q000166:cytology; D011961:Receptors, Fc / Q000276:immunology
D016207:Cytokines; D007070:Immunoglobulin A; D007128:Immunoglobulin Fragments; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007136:Immunoglobulins; D015850:Interleukin-6; D011961:Receptors, Fc